CIK 0001609809 · Non-accelerated filer<br>Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 274326290
- Phone
- 617 945 9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230
- in 4 filings, $2K under 10b5-1 plans
Net −$2,230. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-16 | Henn Matthew R See Remarks | Sale 10b5-1 | −77 | $7.28 | $561 | 4,383 |
| 2025-05-15 | Young Teresa L. See Remarks | Option exercise 10b5-1 | +133 | 5,009 | ||
| 2025-05-15 | Young Teresa L. See Remarks | Option exercise 10b5-1 | +98 | 5,107 | ||
| 2025-05-15 | Young Teresa L. See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −133 | 929 | ||
| 2025-05-15 | Young Teresa L. See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −98 | 1,073 | ||
| 2025-05-15 | Shaff Eric D. CEO and President | Option exercise 10b5-1 | +390 | 9,991 | ||
| 2025-05-15 | Shaff Eric D. CEO and President | Option exercise 10b5-1 | +331 | 10,322 | ||
| 2025-05-15 | Shaff Eric D. CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −390 | 2,735 | ||
| 2025-05-15 | Shaff Eric D. CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −331 | 3,653 | ||
| 2025-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise 10b5-1 | +133 | 7,255 | ||
| 2025-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise 10b5-1 | +111 | 7,366 | ||
| 2025-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Sale 10b5-1 | −79 | $7.28 | $575 | 7,287 |
| 2025-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise · Restricted Stock Units 10b5-1 | −133 | 929 | ||
| 2025-05-15 | DesRosier Thomas Chief Legal Officer and EVP | Option exercise · Restricted Stock Units 10b5-1 | −111 | 1,224 | ||
| 2025-05-15 | Henn Matthew R See Remarks | Option exercise 10b5-1 | +140 | 4,362 | ||
| 2025-05-15 | Henn Matthew R See Remarks | Option exercise 10b5-1 | +98 | 4,460 | ||
| 2025-05-15 | Henn Matthew R See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −140 | 985 | ||
| 2025-05-15 | Henn Matthew R See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −98 | 1,073 | ||
| 2025-04-10 | Biondi Paul Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2025-04-10 | Fraser Claire Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 |
Page 7 of 13 · 254 trades